Affimed N.V. (NASDAQ:AFMD) will hold its 2Q20 earnings conference call with the financial community on 11th August 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at www.affimed.com
Earnings Expectation
Affimed N.V. is reporting second quarter financial results on Tuesday 11th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, AFMD is expected to report 2Q20 loss of $ 0.16 per share from revenue of $ 5.52 million.
For the full year, analysts anticipate top line of $ 23.22 million, while looking forward to loss of $ 0.6 per share bottom line.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The companys products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
